Terconazole
Triazole Derivatives
- Drug class
- Triazole Derivatives
- Availability
- Prescription only
- Routes
- Vaginal
- Markets covered
- 2
- Products on record
- 2
- FDA reports (12 mo)
- 29
Overview
Terconazole is an active pharmaceutical ingredient in the Triazole Derivatives group (G01AG). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | January 28, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). 4% is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Sources & citations
- [1]FDA DailyMed · 10e84353-93d2-46… · revised January 28, 2026 [PDF]
- [2]Health Canada (DPD) · 02247651 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.